Literature DB >> 27773373

Is sentinel lymph node biopsy indicated in patients with a diagnosis of ductal carcinoma in situ? A systematic literature review and meta-analysis.

Hiba El Hage Chehade1, Hannah Headon2, Umar Wazir2, Houssam Abtar2, Abdul Kasem2, Kefah Mokbel2.   

Abstract

BACKGROUND: Recent discussion has suggested that some cases of ductal carcinoma in situ (DCIS) with high risk of invasive disease may require sentinel lymph node biopsy (SLNB).
METHODS: Systematic literature review identified 48 studies (9,803 DCIS patients who underwent SLNB). Separate analyses for patients diagnosed preoperatively by core sampling and patients diagnosed postoperatively by specimen pathology were conducted to determine the percentage of patients with axillary nodal involvement. Patient factors were analyzed for associations with risk of nodal involvement.
RESULTS: The mean percentage of positive SLNBs was higher in the preoperative group (5.95% vs 3.02%; P = .0201). Meta-regression analysis showed a direct association with tumor size (P = .0333) and grade (P = .00839) but not median age nor tumor upstage rate.
CONCLUSIONS: The SLNB should be routinely considered in patients with large (>2 cm) high-grade DCIS after a careful multidisciplinary discussion. In the context of breast conserving surgery, the SLNB is not routinely indicated for low- and intermediate-grade DCIS, high-grade DCIS smaller than 2 cm, or pure DCIS diagnosed by definitive surgical excision. Crown
Copyright © 2016. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast cancer; Ductal carcinoma in situ; Sentinel lymph node biopsy

Mesh:

Year:  2016        PMID: 27773373     DOI: 10.1016/j.amjsurg.2016.04.019

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  8 in total

1.  A Network Meta-Analysis of Surgical Treatment in Patients With Early Breast Cancer.

Authors:  Yu Gui; Xunzhou Liu; Xianchun Chen; Xi Yang; Shichao Li; Qingwen Pan; Xiangdong Luo; Li Chen
Journal:  J Natl Cancer Inst       Date:  2019-09-01       Impact factor: 13.506

Review 2.  Addressing the problem of overtreatment in breast cancer.

Authors:  Linda M Pak; Monica Morrow
Journal:  Expert Rev Anticancer Ther       Date:  2022-05-19       Impact factor: 3.627

Review 3.  Is invasion a necessary step for metastases in breast cancer?

Authors:  Steven A Narod; Victoria Sopik
Journal:  Breast Cancer Res Treat       Date:  2018-01-20       Impact factor: 4.872

4.  Preoperative Delays in the Treatment of DCIS and the Associated Incidence of Invasive Breast Cancer.

Authors:  William H Ward; Lyudmila DeMora; Elizabeth Handorf; Elin R Sigurdson; Eric A Ross; John M Daly; Allison A Aggon; Richard J Bleicher
Journal:  Ann Surg Oncol       Date:  2019-09-27       Impact factor: 5.344

5.  Sentinel lymph node biopsy in patients with ductal carcinoma in situ: systematic review and meta-analysis.

Authors:  Matthew G Davey; Colm O'Flaherty; Eoin F Cleere; Aoife Nohilly; James Phelan; Evan Ronane; Aoife J Lowery; Michael J Kerin
Journal:  BJS Open       Date:  2022-03-08

Review 6.  Multiple Metastases of the Liver and Lung After Breast-Conserving Surgery for Ductal Carcinoma In Situ Without Microinvasion of the Breast: A Case Report and Literature Review.

Authors:  Zhen Wang; Xinyang Zhang; Huiyang Ren; Lei Zhang; Bo Chen
Journal:  Front Oncol       Date:  2022-04-11       Impact factor: 5.738

7.  Ductal Carcinoma in situ after Core Needle Biopsy: In Which Cases Is a Sentinel Node Biopsy Necessary?

Authors:  Robbert J H van Leeuwen; Birgitta Kortmann; Herman Rijna
Journal:  Breast Care (Basel)       Date:  2019-08-29       Impact factor: 2.860

8.  Ductal Carcinoma in situ: Underestimation of Percutaneous Biopsy and Positivity of Sentinel Lymph Node Biopsy in a Brazilian Public Hospital.

Authors:  Rafael da Silva Sá; Angela Flávia Logullo; Simone Elias; Gil Facina; Vanessa Monteiro Sanvido; Afonso Celso Pinto Nazário
Journal:  Breast Cancer (Dove Med Press)       Date:  2021-06-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.